文献速递前列腺癌

前列腺癌mpMRI与68Ga-PSMA-PET/CT及联合成像的段级比较

Segment-based comparison of multiparametric MRI, Gallium-68-PSMA-PET/CT and combined imaging with histopathology in prostate cancer.
PubMed 文献 · BJU Int · 2026-10-18

该研究基于DEPROMP试验中97例接受根治性前列腺切除术的男性,将前列腺分为36个解剖段,比较mpMRI、68Ga-PSMA-PET/CT及联合成像与全切片病理的段级诊断性能。结果显示联合成像检测率79.1%、敏感性25.8%、特异性90.5%,均优于单模态,提示结构成像与分子成像具有互补价值。

要点

  • 联合成像段级检测率79.1%,高于mpMRI的74.1%和PSMA-PET/CT的72.2%。
  • 联合成像敏感性25.8%优于单模态,但特异性90.5%略低于mpMRI的97.3%。
  • 三种成像段级AUC均不高(0.62~0.69),段级定位准确性有限。

核心结论

  • 在段级水平,mpMRI与68Ga-PSMA-PET/CT诊断准确性相当,均表现为高特异性但敏感性有限。
  • 两者联合可提高敏感性和整体检测性能,体现结构成像与分子成像对前列腺癌病灶定位和精准管理的互补价值。

研究设计与样本

  • 来自前瞻性、干预性II期DEPROMP试验的97例接受根治性前列腺切除术并完成全切片病理评估的男性。
  • 所有参与者活检前接受mpMRI和PSMA-PET/CT,mpMRI按PI-RADS v2.1判读,PSMA-PET/CT按PROMISE miTNM标准判读。
  • 前列腺按PI-RADS v2.1分区图分为36个解剖段,共分析3492个前列腺段,每段与根治标本病理结果对应。

主要发现

  • 检测率:mpMRI为74.1%(95%CI 72.6-75.5),PSMA-PET/CT为72.2%(95%CI 70.6-73.6),联合为79.1%(95%CI 77.7-80.4)。
  • 敏感性和特异性:mpMRI为13.4%和97.3%,PSMA-PET/CT为18.5%和92.7%,联合为25.8%和90.5%。
  • 阈值ROC分析AUC:PI-RADS为0.62(95%CI 0.54-0.69),最大标准化摄取值(SUVmax)为0.68(95%CI 0.63-0.74),分子成像PSMA(miPSMA)为0.69(95%CI 0.65-0.74)。

临床怎么用

  • 段级诊断中应知晓mpMRI和PSMA-PET/CT单独敏感性低,阴性段不能排除病理癌。
  • 联合mpMRI与PSMA-PET/CT可提高病灶检出敏感性,有助于活检靶点选择和精准管理。
  • 高特异性提示阳性段对病理癌的确认价值较高,但需结合临床综合判断。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare the segment-based diagnostic performance of multiparametric magnetic resonance imaging (mpMRI), Gallium-68-prostate-specific membrane antigen-positron emission tomography/computed tomography (68Ga-PSMA-PET/CT), for detecting histopathologically confirmed prostate cancer (PCa). PATIENTS AND METHODS: This analysis included 97 men from the prospective, interventional, phase II DEPROMP (DEtection rate of clinically significant PROstate cancer by mpMRI and PSMA-PET/CT fusion biopsy) trial who underwent radical prostatectomy with whole-mount histopathological evaluation. All participants received mpMRI and PSMA-PET/CT prior to biopsy. The mpMRI was interpreted according to Prostate Imaging-Reporting and Data System (PI-RADS) version(v)2.1, and PSMA-PET/CT according to Prostate Cancer Molecular Imaging Standardised Evaluation (PROMISE) molecular imaging Tumour-Node-Metastasis (miTNM) criteria. The prostate was divided into 36 anatomical segments based on the PI-RADS v2.1 sector map. Each segment was correlated with histopathological findings from prostatectomy specimens. For each imaging modality, detection rates, sensitivity, specificity, and area under the receiver operating characteristic curve (AUC) were calculated at the segment level. RESULTS: A total of 3492 prostate segments were analysed. Detection rates were 74.1% (95% confidence interval [CI] 72.6-75.5) for mpMRI, 72.2% (95% CI 70.6-73.6) for PSMA-PET/CT, and 79.1% (95% CI 77.7-80.4) for the combined use of mpMRI and PSMA-PET/CT. Sensitivity and specificity were 13.4% and 97.3% for mpMRI, 18.5% and 92.7% for PSMA-PET/CT, and 25.8% and 90.5% for combined mpMRI and PSMA-PET/CT, respectively. Threshold-based receiver operating characteristic analyses yielded an AUC of 0.62 (95% CI 0.54-0.69) for PI-RADS, 0.68 (95% CI 0.63-0.74) for maximum standardised uptake value, and 0.69 (95% CI 0.65-0.74) for molecular imaging PSMA. CONCLUSION: At the segment level, mpMRI and PSMA-PET/CT showed comparable diagnostic accuracy with high specificity but limited sensitivity. Their combination improved sensitivity and overall detection performance, underscoring the complementary value of structural and molecular imaging for lesion localisation and precision management in PCa.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Schmidt CJ, Bernhardt M, Kristiansen G, et al. Segment-based comparison of multiparametric MRI, Gallium-68-PSMA-PET/CT and combined imaging with histopathology in prostate cancer. BJU Int. 2026. PMID: 42893832. doi:10.1111/bju.70497

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。